Novavax shareholder calls for sale of vaccine maker Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 14 October, 2025

The only optichannel HCP engagement platform in biopharma helps you reimagine what’s possible—driving agile, real-time campaigns with such clear ROI that 100% of clients renew. sponsored by PharmaForceIQ

presented by In sight: Ad­vanc­ing cell ther­a­py for reti­nal dis­ease

SPOTLIGHT Bioregnum Is the worst over? Biopharma dealmaking shows an uptick in third quarter

news Obesity biotech Kailera gets $600M to start Phase 3 this year Exclusive: Bristol Myers, insitro extend research deal to find a drug for new ALS target Novavax's second-largest shareholder calls for sale of vaccine maker Johnson & Johnson to spin out orthopedics business Takeda expands de novo protein research by signing second deal with AI specialist Nabla Bio

Oct 21 11:00am ET AI in life sciences: Reimagining teams, technology and partnerships for the future sponsored by Zaidyn by ZS

Biopharma is entering a new era of AI-driven discovery and precision medicine — but growth is challenged by regulatory shifts and global uncertainty. Join us in London to hear from the leaders shaping what’s next. UTMs:

endpoints pharma Three big questions ahead of third-quarter pharma earnings FDA on pace for lowest number of new drug approvals since 2022 FDA hands OAI classification to Novo Nordisk’s troubled Indiana site California enacts state law building on PBM reforms

in case you missed it 1. A fresh biotech has a radical plan to treat inflammation and allergies, setting its sights on Xolair 2. Tvardi's stock crashes as STAT3 drug fails in Phase 2 after extensive dropouts from side effects 3. Novo Nordisk quits cell therapy as restructure continues 4. News Briefing SystImmune’s $250M milestone; Teva’s Uzedy approved to treat bipolar disorder 5. Moderna previews cancer antigen therapy in melanoma ahead of ESMO 6. Gilead, Arcus’ TIGIT approach exceeds two years of median survival in Phase 2 gastric cancer trial 7. Regeneron heads to FDA to seek approval for hearing loss gene therapy